Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results ...
INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...
The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback